Mytatrienediol

Mytatrienediol
Clinical data
Other names	SC-6924; Manvene; Anvene; 3-Methoxy-16α-methylestra-1,3,5(10)-triene-16β,17β-diol; 16α-Methylestriol 3-methyl ether; 16β-Hydroxy-16α-methylestradiol 3-methyl ether
Routes of; administration	By mouth
Drug class	Estrogen; Estrogen ether
Identifiers
	IUPAC name (8R,9S,13S,14S,16S,17R)-3-methoxy-13,16-dimethyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-16,17-diol;
CAS Number	5108-94-1;
PubChem CID	5282364;
ChemSpider	4445527;
UNII	1G3TKH1O14;
KEGG	C14242;
ChEBI	CHEBI:34859;
CompTox Dashboard (EPA)	DTXSID1022500 ;
Chemical and physical data
Formula	C20H28O3
Molar mass	316.441 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC12CCC3C(C1CC(C2O)(C)O)CCC4=C3C=CC(=C4)OC;
	InChI InChI=1S/C20H28O3/c1-19-9-8-15-14-7-5-13(23-3)10-12(14)4-6-16(15)17(19)11-20(2,22)18(19)21/h5,7,10,15-18,21-22H,4,6,8-9,11H2,1-3H3/t15-,16-,17+,18-,19+,20+/m1/s1; Key:OOVXZFCPCSVSEM-NADOGSGZSA-N;

Mytatrienediol (developmental code name SC-6924; former tentative brand names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a synthetic steroidal estrogen medication and an estrogen ether which was derived from estriol and was developed for clinical use in the late 1950s but was never marketed. It was investigated as a weak and mildly estrogenic medication for men to treat atherosclerosis, improve serum lipid profiles, and reduce the risk of myocardial infarction. However, while preclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found in clinical trials to produce estrogenic side effects including feminization, breast pain, and gynecomastia in men similarly and comparably to other estrogens such as ethinylestradiol and conjugated estrogens, and its side effects ultimately precluded its use. The medication was also studied to treat bone pain in patients with multiple myeloma, metastatic bone disease, and osteoporosis, with effectiveness seen.